Approval to add the bp/lordotic to the approved product line for the bak interbody fusion system.  The device, as modified, will be marketed under the trade name bp/lordotic and is indicated for use with autogenous bone graft in patients with degenerative disc disease (ddd) at the l4-l5 and/or l5-s1 levels.  These ddd patients may also have up to grade i spondylolisthesis or retrolisthesis at the involved level(s).  Bp/lordotic devices are to be implanted via an open anterior or laparoscopic approach.  Ddd is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies.  These patients should be skeletally mature and have had six months of non-operative treatment.